← back to search

Matthew C. Riddle

Meridian Clinical Research · US
Area of research
Endocrinology, Diabetes and Metabolism · Molecular Biology
Research interest
Research interests include Diabetes Management and Research, Diabetes Treatment and Management, Diabetes, Cardiovascular Risks, and Lipoproteins, and Hyperglycemia and glycemic control in critically ill and hospitalized patients.
h-index
73
citations
26,887
works
313
NIH funding
primary concept
Medicine
email

Recent publications

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
JACC Heart Failure 2023cited by 45position: middledoi
Use of Real-World Data in Population Science to Improve the Prevention and Care of Diabetes-Related Outcomes
Diabetes Care 2023cited by 31position: middledoi
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes
Diabetes Care 2021cited by 405position: firstdoi
Consensus report: definition and interpretation of remission in type 2 diabetes
Diabetologia 2021cited by 116position: firstdoi
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism 2021cited by 85position: firstdoi
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
Annals of Internal Medicine 2021cited by 76position: middledoi
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
New England Journal of Medicine 2020cited by 1,802position: middledoi
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
New England Journal of Medicine 2020cited by 1,163position: middledoi
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
The Lancet Neurology 2020cited by 267position: middledoi
Red and Processed Meats and Health Risks: How Strong Is the Evidence?
Diabetes Care 2020cited by 146position: middledoi
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
The Lancet Diabetes & Endocrinology 2020cited by 144position: middledoi
Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a <i>Diabetes Care</i> Editors’ Expert Forum
Diabetes Care 2020cited by 103position: firstdoi
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
The Lancet 2019cited by 2,975position: middledoi
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
The Lancet 2019cited by 620position: middledoi
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet 2018cited by 1,758position: middledoi
Big Topics for <i>Diabetes Care</i> in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology
Diabetes Care 2018cited by 6position: firstdoi
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a<i>Diabetes Care</i>Editors’ Expert Forum
Diabetes Care 2017cited by 365position: lastdoi
Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide
Diabetes Obesity and Metabolism 2017cited by 186position: middledoi
Diabetes Research and Care Through the Ages
Diabetes Care 2017cited by 20position: middledoi
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
New England Journal of Medicine 2015cited by 2,319position: middledoi
Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
Diabetes Care 2014cited by 258position: middledoi
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
Diabetes Care 2014cited by 174position: middledoi
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia
Diabetes Care 2014cited by 86position: middledoi
Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management
Diabetes Care 2014cited by 62position: lastdoi
Personalized Management of Hyperglycemia in Type 2 Diabetes
Diabetes Care 2013cited by 143position: middledoi
Contributions of Basal and Prandial Hyperglycemia to Total Hyperglycemia in Older and Younger Adults with Type 2 Diabetes Mellitus
Journal of the American Geriatrics Society 2013cited by 40position: lastdoi
Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study
Diabetes Care 2013cited by 20position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

William T. Cefalu · National Institutes of Health8 papers (2013–2023)Hertzel C. Gerstein · McMaster University7 papers (2014–2021)Lawrence A. Leiter · St. Michael's Hospital6 papers (2013–2023)Philippe Gabríel Steg · Mount Sinai Hospital4 papers (2020–2023)Deepak L. Bhatt · Technische Universität Dresden4 papers (2020–2023)Christopher P. Cannon · Harvard University4 papers (2020–2023)John B. Buse · University of North Carolina at Chapel Hill4 papers (2013–2017)Julio Rosenstock · Dallas Diabetes Research Center4 papers (2013–2018)Julia B. Lewis · Vanderbilt University Medical Center4 papers (2020–2023)Renato D. Lópes · Alnylam Pharmaceuticals (United States)4 papers (2020–2023)Michael A. Nauck · Universitätsmedizin Greifswald4 papers (2014–2021)Darren K. McGuire · Saint Luke's Health System4 papers (2020–2023)Michael Szarek · SUNY Downstate Health Sciences University4 papers (2020–2023)Itamar Raz · Thrombolysis in Myocardial Infarction Study Group4 papers (2013–2017)Christopher S. Wilcox · MedStar Georgetown University Hospital3 papers (2020–2023)Michel Komajda · Hôpital Saint Joseph3 papers (2020–2023)Philip Home · Newcastle University3 papers (2013–2014)Silvio E. Inzucchi · Yale University3 papers (2013–2020)Carel W. le Roux · University College Dublin3 papers (2021–2021)Francesco Rubino · King's College London3 papers (2021–2021)